STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1362 by analyst upside · 2026-08-12
DFTX
Definium Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+47.0%
implied upside to consensus target
Current Price $40.91
Consensus Target $60.13
Bull Target $75.0
Bear Target $50.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
11
Hold
0
Sell
0
52-Week Low $8.7
52-Week High $49.7
YTD Return +199.9%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.43
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.7
52-Week High $49.7
Current Price $40.91
Bear Target $50.0
Bull Target $75.0
● Now $40.91 ● Target $60.13
TRADING DATA
Avg Volume 2.8M
YTD Return +199.9%
Analyst Count 15
Consensus Buy
Upside to Target +47.0%
Last Updated 2026-08-12

ANALYST SUMMARY

Definium Therapeutics, Inc. (DFTX) is currently trading at $40.91 with a Wall Street consensus price target of $60.13, implying potential upside of 47.0% over the next 12 months. 15 analysts currently cover DFTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $75.0, while the most cautious has a target of $50.0.

DFTX operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 199.9% year-to-date and is currently trading near the upper end of its 52-week range of $8.7 – $49.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DFTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-06-16 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-08 14% win rate (7 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
Stifel ● Initiated
Buy 2026-04-17 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-16 Building track record
Piper Sandler ● Initiated
Overweight 2026-04-10 14% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
21/30
Consensus clarity
18/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →